Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
-
Published:2023-07-17
Issue:
Volume:14
Page:
-
ISSN:1664-3224
-
Container-title:Frontiers in Immunology
-
language:
-
Short-container-title:Front. Immunol.
Author:
Beavis Ashley C.,Wee Edmund G. -T.,Akis Yildirim Belkis M.,Borthwick Nicola,He Biao,Hanke Tomáš
Abstract
IntroductionThe primary goal of this work is to broaden and enhance the options for induction of protective CD8+ T cells against HIV-1 and respiratory pathogens.MethodsWe explored the advantages of the parainfluenza virus 5 (PIV5) vector for delivery of pathogen-derived transgenes alone and in combination with the in-human potent regimen of simian adenovirus ChAdOx1 prime-poxvirus MVA boost delivering bi-valent mosaic of HIV-1 conserved regions designated HIVconsvX.ResultsWe showed in BALB/c mice that the PIV5 vector expressing the HIVconsvX immunogens could be readily incorporated with the other two vaccine modalities into a single regimen and that for specific vector combinations, mucosal CD8+ T-cell induction was enhanced synergistically by a combination of the intranasal and intramuscular routes of administration.DiscussionEncouraging safety and immunogenicity data from phase 1 human trials of ChAdOx1- and MVA-vectored vaccines for HIV-1, and PIV5-vectored vaccines for SARS-CoV-2 and respiratory syncytial virus pave the way for combining these vectors for HIV-1 and other indications in humans.
Funder
Mauritius Research Council
European and Developing Countries Clinical Trials Partnership
European Commission
Publisher
Frontiers Media SA
Subject
Immunology,Immunology and Allergy